von willebrand factor/coagulation factor viii complex (human)
Drug data last refreshed 1w ago · AI intelligence enriched 2w ago
Wilate is a plasma-derived von Willebrand Factor/Coagulation Factor VIII complex indicated for the treatment of von Willebrand disease and hemophilia A. It replaces deficient or dysfunctional clotting factors to restore hemostatic function in patients with inherited bleeding disorders. The drug is administered intravenously as a powder for reconstitution.
LOE-stage product with moderate competitive pressure (30/100) signals transition planning and potential team restructuring.
Blood Coagulation Factors
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Wilate offers career experience in specialty hemostasis, plasma-derived biologics, and niche market management within a LOE-approaching product lifecycle. Professionals joining this team should expect focus on market defense, payer management, and potential transition planning rather than launch-phase growth.
Worked on Wilate - von Willebrand Factor/Coagulation Factor VIII Complex (Human) at Octapharma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo